small molecule

ACUVUE THERAVISION WITH KETOTIFEN

KETOTIFEN FUMARATE

Loss of exclusivityJune 2030latest FDA-listed patent expiry

CompanyJOHNSON AND JOHNSON VISION CARE INC

Drug detail

Brand name	ACUVUE THERAVISION WITH KETOTIFEN
Active ingredient	KETOTIFEN FUMARATE
Strength	EQ 19MCG BASE
Dosage form	DRUG-ELUTING CONTACT LENS
Route	OPHTHALMIC
Modality	Small molecule
FDA approval	February 2022
Marketing status	DISCN

Listed patents

Patent	Expires	Type
9962376	June 2030	product
9474746	March 2028	product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.